Prevalence of sarcopenia and respiratory sarcopenia after chimeric antigen receptor gene-modified T cell therapy

Prevalence of sarcopenia and respiratory sarcopenia after chimeric antigen receptor gene-modified T cell therapy - Prevalence of sarcopenia and respiratory sarcopenia after CAR-T cell therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058380

Enrollment

100

Registered

2025-07-07

Start date

2025-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma, multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients scheduled to undergo CAR-T cell therapy during hospitalization

Exclusion criteria

Exclusion criteria: Those with severe heart disease, lung disease, or brain or nervous system disorders; those with pacemakers; and those with other systemic conditions that are difficult to evaluate.

Design outcomes

Primary

Measure	Time frame
Skeletal muscle index before and after CAR-T cell therapy	—

Secondary

Measure	Time frame
Hand grip strength, walking speed, and respiratory muscle strength before and after CAR-T cell therapy	—

Countries

Japan

Contacts

Public ContactNobuyoshi Nisikado

Hyogo Medical University Hospital Rehabilitation Department

nnishikado@gmail.com0798456111

Outcome results